National Institute of Health (NIH)

You are here

A5264: A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067

Sponsor:

  • AIDS Clinical Trials Group

Collaborator:

  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Information provided by (Responsible Party):
  • AIDS Clinical Trials Group

A5288: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (MULT-OCTAVE)

The aim is to test a strategy of using resistance testing to choose the optimal ART regimen in those failing 2nd line Therapy. 

Sponsor:

  • AIDS Clinical Trials Group

Collaborator:

  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Information provided by (Responsible Party):
  • AIDS Clinical Trials Group

Strategic Timing of AntiRetroviral Treatment (START)

The main objective is to assess the development of serious illness or AIDS when ART is initiated at fairly highCD4+ Compared to waiting until the CD4+ count is at the level where there is good evidence for starting therapy.